Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
- Written by PR Newswire
- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study.
- The study is expected to be completed in Q2 2024, and the topline results are anticipated in Q3 2024.
TAIPEI, May 31, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals, a biopharmaceutical company focusing on breakthrough medical aesthetics and inflammatory medicine...
